Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients:: The Heart Outcomes Prevention Evaluation (HOPE)-2 trial

被引：42

作者：

Lonn, E ^{[1
]}

Held, C ^{[1
]}

Arnold, JMO ^{[1
]}

Probstfield, J ^{[1
]}

McQueen, M ^{[1
]}

Micks, M ^{[1
]}

Pogue, J ^{[1
]}

Sheridan, P ^{[1
]}

Bosch, J ^{[1
]}

Genest, J ^{[1
]}

Yusuf, S ^{[1
]}

Lonn, E ^{[1
]}

Yusuf, S ^{[1
]}

Genest, J ^{[1
]}

Arnold, JMO ^{[1
]}

Avezum, A ^{[1
]}

Bosch, J ^{[1
]}

Choy, J ^{[1
]}

Dagenais, G ^{[1
]}

Davies, R ^{[1
]}

Fisher, M ^{[1
]}

Fodor, G ^{[1
]}

Hamalainen, T ^{[1
]}

Heyndrickx, G ^{[1
]}

Hoeschen, R ^{[1
]}

Klein, W ^{[1
]}

Kuritzky, R ^{[1
]}

Mann, J ^{[1
]}

McQueen, M ^{[1
]}

Micks, M ^{[1
]}

Mitchell, B ^{[1
]}

Ostergren, J ^{[1
]}

Piegas, L ^{[1
]}

Pogue, J ^{[1
]}

Probstfield, J ^{[1
]}

Sleight, P ^{[1
]}

Spinas, G ^{[1
]}

Sussex, B ^{[1
]}

Teo, K ^{[1
]}

Title, L ^{[1
]}

Tsuyuki, R ^{[1
]}

Arnold, JMO ^{[1
]}

Avezum, A ^{[1
]}

Arnold, A ^{[1
]}

Auger, P ^{[1
]}

Bata, I ^{[1
]}

Bernstein, V ^{[1
]}

Bourassa, M ^{[1
]}

Dagenais, G ^{[1
]}

Fodor, G ^{[1
]}

机构：

[1] Hamilton Hlth Sci Corp, Hamilton, ON L8L 2X2, Canada

来源：

CANADIAN JOURNAL OF CARDIOLOGY | 2006年 / 22卷 / 01期

基金：

加拿大健康研究院;

关键词：

atherosclerosis; clinical trials; coronary disease; homocysteine; myocardial infarction; stroke;

D O I：

10.1016/S0828-282X(06)70238-0

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BACKGROUND: Epidemiological studies suggest that mild to moderate elevation in plasma homocysteine concentration is associated with increased risk of atherothrombotic cardiovascular (CV) disease. Simple, inexpensive and nontoxic therapy with folic acid and vitamins B-6 and B-12 reduces plasma homocysteine levels by approximately 25% to 30% and may reduce CV events. Therefore, a large, randomized clinical trial - the Heart Outcomes Prevention Evaluation (HOPE)-2 study - is being conducted to evaluate this therapy in patients at high risk for CV events. OBJECTIVES: To evaluate whether long-term therapy with folic acid and vitamins B-6 and B-12 reduces the risk of major CV events in a high-risk population. The primary study outcome is the composite of death from CV causes, myocardial infarction and stroke. METHODS: A total of 5522 patients aged 55 years or older with preexisting CV disease or with diabetes and additional risk factor(s) at 145 centres in 13 countries were randomly assigned to daily therapy with combined folic acid 2.5 mg, vitamin B-6 50 mg and vitamin B-12 1 mg, or to placebo. Follow-up will average five years, to be completed by the end of 2005. RESULTS: The patients' baseline characteristics confirmed their high-risk status. Baseline homocysteine levels varied between countries and regions. HOPE-2 is one of the largest trials of folate and vitamins B-6 and B-12 and is expected to significantly contribute to the evaluation of the role of homocysteine lowering in CV prevention.

引用

页码：47 / 53

页数：7

共 31 条

[1]

*B VIT TREATM TRIA, IN PRESS AM HEART J

[2]

Baker RI, 2002, CEREBROVASC DIS, V13, P120

[3] The women's antioxidant cardiovascular study: Design and baseline characteristics of participants [J].

Bassuk, SS ;

Albert, CM ;

Cook, NR ;

Zaharris, E ;

MacFadyen, JG ;

Danielson, E ;

Van Denburgh, M ;

Buring, JE ;

Manson, JE .

JOURNAL OF WOMENS HEALTH, 2004, 13 (01) :99-117

[4] HETEROZYGOSITY FOR HOMOCYSTINURIA IN PREMATURE PERIPHERAL AND CEREBRAL OCCLUSIVE ARTERIAL-DISEASE [J].

BOERS, GHJ ;

SMALS, AGH ;

TRIJBELS, FJM ;

FOWLER, B ;

BAKKEREN, JAJM ;

SCHOONDERWALDT, HC ;

KLEIJER, WJ ;

KLOPPENBORG, PWC .

NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (12) :709-715

[5]

BOONA KH, 2005, EUR SOC CARD C STOCK

[6] Total homocysteine lowering artery disease patients in the treatment among coronary era of folic acid-fortified cereal grain flour [J].

Bostom, AG ;

Jacques, PF ;

Liaugaudas, G ;

Rogers, G ;

Rosenberg, IH ;

Selhub, J .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (03) :488-491

[7] A QUANTITATIVE ASSESSMENT OF PLASMA HOMOCYSTEINE AS A RISK FACTOR FOR VASCULAR-DISEASE - PROBABLE BENEFITS OF INCREASING FOLIC-ACID INTAKES [J].

BOUSHEY, CJ ;

BERESFORD, SAA ;

OMENN, GS ;

MOTULSKY, AG .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (13) :1049-1057

[8]

Braunwald E, 2004, NEW ENGL J MED, V351, P2058

[9] Homocysteine and risk of ischemic heart disease and stroke -: A meta-analysis [J].

Clarke, R ;

Collins, R ;

Lewington, S ;

Donald, A ;

Alfthan, G ;

Tuomilehto, J ;

Arnesen, E ;

Bonaa, K ;

Blacher, J ;

Boers, GHJ ;

Bostom, A ;

Bots, ML ;

Grobee, DE ;

Brattström, L ;

Breteler, MMB ;

Hofman, A ;

Chambers, JC ;

Kooner, JS ;

Coull, BM ;

Evans, RW ;

Kuller, LH ;

Evers, S ;

Folsom, AR ;

Freyburger, G ;

Parrot, F ;

Genst, J ;

Dalery, K ;

Graham, IM ;

Daly, L ;

Hoogeveen, EK ;

Kostense, PJ ;

Stehouwer, CDA ;

Hopknis, PN ;

Jacques, P ;

Selhub, J ;

Luft, FC ;

Jungers, P ;

Lindgren, A ;

Lolin, YI ;

Loehrer, F ;

Fowler, B ;

Mansoor, MA ;

Malinow, MR ;

Ducimetiere, P ;

Nygard, O ;

Refsum, H ;

Vollset, SE ;

Ueland, PM ;

Omenn, GS ;

Beresford, SAA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (16) :2015-2022

[10] HYPERHOMOCYSTEINEMIA - AN INDEPENDENT RISK FACTOR FOR VASCULAR-DISEASE [J].

CLARKE, R ;

DALY, L ;

ROBINSON, K ;

NAUGHTEN, E ;

CAHALANE, S ;

FOWLER, B ;

GRAHAM, I .

NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (17) :1149-1155

← 1 2 3 4 →